ArticleJournal of virology2008
Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.
Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 92 citations in OpenAlex.
- Remodeling of immune system functions by extracellular vesicles.Frontiers in immunology · 2025Article
- Immunoregulatory molecule expression on extracellular microvesicles in people living with HIV.Frontiers in immunology · 2024Article
- Immune Responses in Lung Granulomas during Mtb/HIV Co-Infection: Implications for Pathogenesis and Therapy.Pathogens (Basel, Switzerland) · 2023Review
- CD27Frontiers in immunology · 2023Article
- Autologous blood extracellular vesicles and specific CD4Frontiers in immunology · 2022Article
- SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.Microorganisms · 2021Review
- The long road to TRAIL therapy: a TRAILshort detour.Oncotarget · 2021Article
- Pulmonary Immune Dysregulation and Viral Persistence During HIV Infection.Frontiers in immunology · 2021Review
- Granulocyte-Derived Extracellular Vesicles Activate Monocytes and Are Associated With Mortality in Intensive Care Unit Patients.Frontiers in immunology · 2018Article
- Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection.Frontiers in microbiology · 2018Article
- HMGB1 Is Involved in IFN-α Production and TRAIL Expression by HIV-1-Exposed Plasmacytoid Dendritic Cells: Impact of the Crosstalk with NK Cells.PLoS pathogens · 2016Article
- Elevated Abundance, Size, and MicroRNA Content of Plasma Extracellular Vesicles in Viremic HIV-1+ Patients: Correlations With Known Markers of Disease Progression.Journal of acquired immune deficiency syndromes (1999) · 2015Article
- Article
- Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.PLoS pathogens · 2015Article
- Determinants of HIV-induced brain changes in three different periods of the early clinical course: A data mining analysis.NeuroImage. Clinical · 2015Article
- Article
- Microbial exposure alters HIV-1-induced mucosal CD4+ T cell death pathways Ex vivo.Retrovirology · 2014Article
- Article
- Article
- Coronary heart disease alters intercellular communication by modifying microparticle-mediated microRNA transport.FEBS letters · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Funding
Abstract
The death of CD4(+) CCR5(+) T cells is a hallmark of human immunodeficiency virus (HIV) infection. We studied the plasma levels of cell death mediators and products--tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), Fas ligand, TNF receptor type 2 (TNFR-2), and plasma microparticles--during the earliest stages of infection following HIV type 1 (HIV-1) transmission in plasma samples from U.S. plasma donors. Significant plasma TRAIL level elevations occurred a mean of 7.2 days before the peak of plasma viral load (VL), while TNFR-2, Fas ligand, and microparticle level elevations occurred concurrently with maximum VL. Microparticles had been previously shown to mediate immunosuppressive effects on T cells and macrophages. We found that T-cell apoptotic microparticles also potently suppressed in vitro immunoglobulin G (IgG) and IgA antibody production by memory B cells. Thus, release of TRAIL during the onset of plasma viremia (i.e., the eclipse phase) in HIV-1 transmission may initiate or amplify early HIV-1-induced cell death. The window of opportunity for a HIV-1 vaccine is from the time of HIV-1 transmission until establishment of the latently infected CD4(+) T cells. Release of products of cell death and subsequent immunosuppression following HIV-1 transmission could potentially narrow the window of opportunity during which a vaccine is able to extinguish HIV-1 infection and could place severe constraints on the amount of time available for the immune system to respond to the transmitted virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.